FEB 27, 2017 06:05 AM PST

Study Links Immunotherapy Response To Gut Microbiome

WRITTEN BY: Xuan Pham

Immunotherapy, the technique of using the immune system to fight off disease, is one of the most promising avenues for anticancer treatments. However, even with the help of the immune system, not all immunotherapy drugs produce the same response across patients. This variability has been attributed to genetic differences between individuals. And now, a new study reports another cause for drug variability: the bacteria residing in patients’ guts.

In studying the melanoma patients’ variable response to an immunotherapy, researchers at the University of Texas MD Anderson Cancer Center identified a crucial link with the patients’ gut microbiome. Specifically, those with a more diverse microbiome showed better response to the immunotherapy, which led to better outcomes.

The immunotherapy under investigation involves PD-1 immune checkpoint inhibitors. This drug works by blocking a programmed death receptor in the body’s immune cells, allowing these cells to perk up longer and attack the tumor. But while effective, it doesn’t work for everybody. “Anti-PD1 immunotherapy is effective for many, but not all, melanoma patients and responses aren't always durable,” said Jennifer Wargo, an associate professor of Surgical Oncology, and the study’s senior author.

Wargo and her team analyzed the microbiome of 233 melanoma patients through oral swab and fecal samples. They identified a subset of patients who received anti-PD-1 therapy, and classified that group to those who responded and those who didn’t.

This revealed a striking pattern about the microbiome. In particular, Clostridiales bacteria were found in high abundance in the guts of responders. Furthermore, these people had a more diverse range of bacteria. By contrast, those who didn’t respond to immunotherapy had more uniform bacteria species, including a higher concentration of Bacteroidales bacteria.

“Our findings point to two potential impacts from additional research – analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment,” said Wargo, who is also the co-leader of the Melanoma Moon Shot program.

So far, the results represent the first link between immunotherapy response and microbiome influence. However, to establish causal relationship between these two factors would require careful clinical trials, which Wargo say will begin later this year. Such studies will provide context as to which bacteria are truly beneficial, and how we can modulate these microorganisms to give patients better outcomes.

Additional sources: MD Anderson Cancer Center

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
AUG 02, 2018
Genetics & Genomics
AUG 02, 2018
The Genetic Hotspots That Can Lead to Cancer
In some of our body's tissues, cells have to replicate many times. That introduces a chance for new genetic errors every time....
SEP 26, 2018
Cancer
SEP 26, 2018
Rare Cancer the Focus of Mesothelioma Awareness Day
More than 2,500 Americans are diagnosed with mesothelioma cancer each year. The cancer is rare but very serious - most patients diagnosed with the disease live just a short 12 to 21 months....
OCT 06, 2018
Genetics & Genomics
OCT 06, 2018
Genetic Mutation Linked to Increased Pancreatic Cancer Risk in Women
In a first, researchers have found a genetic mutation that has a sex-specific effect on pancreatic cancer risk....
NOV 20, 2018
Cell & Molecular Biology
NOV 20, 2018
A Warning About Using Epigenetic Modifiers as Therapeutic Targets
In the long run, some cancer therapeutics may be doing more harm than good....
NOV 26, 2018
Cell & Molecular Biology
NOV 26, 2018
New Insight Into the Machinery That Drives Cell Death
When cells are worn out and damaged or diseased, they can initiate a self-destruct sequence called apoptosis....
Loading Comments...